🔎 Trials Near Me

Domov › Akutna bifentipska levkemija › North Carolina

Klinične študije za Akutna bifentipska levkemija v North Carolina

11 študij za Akutna bifentipska levkemija išče udeležence na lokacijah v North Carolina.

Mesta v North Carolina

Uradno besedilo študije (angleško)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • in še 2
Vključevanje udeležencevFaza 2
365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Duke University Medical Center, Durham
Vključevanje udeležencevFaza 1/2
30 Days · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • in še 4
Vključevanje udeležencevFaza 3
365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Mission Hospital, Asheville
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • in še 4
Vključevanje udeležencevFaza 1/2
Do 22 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04726241

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

  • Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Vključevanje udeležencevFaza 2
Starost 1–18 · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT06390319

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Vključevanje udeležencevFaza 1/2
Starost 13–90 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06533579

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

  • Novant Health Presbyterian Hemby Children's Hospital, Charlotte
Vključevanje udeležencevFaza 4
Starost 1–18 · Vsi spoli · Posodobljeno 14. jul. 2026 · NCT06289673

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • in še 4
Vključevanje udeležencevOpazovalna študija
Starost 65 in več · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT01137825

A Study of Revumenib and Mezigdomide in People With Leukemia

  • University of North Carolina (Data Collection Only), Chapel Hill
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 22. jun. 2026 · NCT07356154

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Vključevanje udeležencevOpazovalna študija
Starost 18–120 · Vsi spoli · Posodobljeno 27. okt. 2025 · NCT01137643

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Carolina-Levine Children's Hospital, Charlotte
Vključevanje udeležencevFaza 1
Starost 1–21 · Vsi spoli · Posodobljeno 6. dec. 2024 · NCT05476770

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.